Comparative Effectiveness of Sodium-glucose Cotransporter 2 Inhibitors Versus Renin-Angiotensin System Inhibitors in Chronic Kidney Disease.
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have demonstrated cardiorenal benefits in patients with chronic kidney disease (CKD) receiving background renin-angiotensin system inhibitor (RASi) therapy. We compared the effectiveness of SGLT2is versus RASis on the risks of heart failure (HF) development, kidney di...